We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone deacetylase inhibitor (HDACi), PCI-24781. PCI-24781 was studied alone and combined with bortezomib in Hodgkin lymphoma (L428) and non-Hodgkin's lymphoma cell lines (Ramos, HF1, SUDHL4). PCI-24781 induced dose-dependent apoptosis that was associated with prominent G0/G1 arrest, decreased Sphase, increased p21 protein expression, and production of reactive oxygen species (ROS). Furthermore, PCI-24781-induced apoptosis was shown to be ROS-and caspase-dependent. Combined PCI-24781 and bortezomib exposure resulted in strong synergistic apoptosis in all cell lines (combination indices 0.19-0.6).
Introduction
Lymphoid malignancies are caused in part by genetic and epigenetic deregulation of tumor suppressor genes. (1) The process of histone deacetylation is a well-characterized epigenetic modification.(2, 3) Histone deacetylases (HDAC) and histone acetylases are enzymes that have been shown to be aberrantly expressed or regulated in malignant tissues, resulting in inhibition of certain tumor suppressor genes, thereby allowing expression of the malignant phenotype. By inhibiting deacetylation of histones and allowing acetyl groups to remain on histones, HDAC inhibitors (HDACi) promote an open chromatin structure that allows gene transcription in relevant tumor suppressor genes that may favor tumor cell apoptosis.
The biological effects of HDACi includes reversion of the transformed phenotype, inhibition of proliferation, cell cycle arrest, induction of differentiation, and apoptosis in tumor cell lines.(4-6) They have also been shown to generate reactive oxygen species (ROS) in solid tumor and leukemia cells (5, (7) (8) (9) , which may contribute to the mechanism in these cell types. The novel HDACi, PCI-24781 (Pharmacyclics, Inc), is a broad spectrum phenyl hydroxamic acid-based, orally bioavailable compound currently in clinical trials for the treatment of neoplastic diseases. (10, 11) It has activity in solid tumors including colorectal carcinoma in Phase I trials (12) and it is being evaluated in Phase II trials in a variety of malignancies, including lymphoma. We evaluated the cytotoxicity and mechanism of action of HDACi PCI-24781, in Hodgkin lymphoma and non-Hodgkin's lymphoma cell lines.
Bortezomib is a proteasome inhibitor that received FDA approval in the United States for relapsed multiple myeloma and more recently for relapsed mantle cell lymphoma, where cell death has been associated with increased ROS. (13) (14) (15) Inhibition of proteasome activity by bortezomib results in stabilization of IĸBa with resultant NF-ĸB inhibition as well as stabilization of p53 and Bax, leading to apoptosis. In addition, in vitro studies in solid tumors and hematologic malignancies (multiple myeloma and leukemia) have shown synergy when bortezomib and HDACi are combined. (16) (17) (18) (19) (20) There is however, little information on the activity and mechanism of this combination in lymphoma, with only one prior report in lymphoma (mantle cell histology)
where HDACi has been tested in combination with bortezomib. (18) We hypothesized that concomitant exposure of PCI-24781 and bortezomib might enhance apoptosis in other histologic subtypes of lymphoma (follicular lymphoma, diffuse large B-cell lymphoma, and Burkitt lymphoma) through ROS-related mechanisms. We show here that the broad spectrum HDACi, PCI-24781, induced dose-dependent apoptosis in Hodgkin lymphoma and non-Hodgkin's lymphoma cell lines, which was dependent on caspase and ROS production. Further, it exhibited strong synergy with bortezomib, inducing ROS-dependent apoptosis in these cells. We analyzed the mechanisms of action of PCI-24781, bortezomib, and the combination by gene expression profiling in lymphoma cells and demonstrated that apoptosis occurred through interacting mechanisms including downregulation of oxidative stress response and several proteasome and NF-ĸB pathways, which were likely responsible for the observed synergy in these tumor cells.
Materials and Methods

Cell lines and reagents.
The L428 Hodgkin lymphoma cell line and the Ramos (Burkitt lymphoma), HF1 (follicular lymphoma), and SUDHL4 (large B-cell lymphoma) non-Hodgkin's lymphoma cell lines were cultured in RPMI1640 (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS), L-glutamine, and penicillin/streptomycin (Invitrogen, Carlsbad, CA). Cells were maintained at 37°C with 5% CO 2 . Bortezomib was provided by Millennium Pharmaceuticals (Cambridge, MA) and PCI-24781 was provided by Pharmacyclics Inc.
(Sunnyvale, CA). Q-VD-OPh was used for pan-caspase inhibition (Calbiochem, San Diego CA), 6-carboxy-2'7'-dichlorodihydrofluorscein (H 2 DCF-DA) for ROS, JC-1 and valinomycin, (Molecular Probes, Eugene, OR) for mitochondrial membrane potential, and catalase was obtained from Sigma-Aldrich (St. Louis, MO).
Antibodies for caspase 8, caspase 9, caspase 3, acetyl histone H3 and H4, PARP (Cell Signaling, Beverly, MA), c-Myc (BD Pharmingen, San Diego, CA), cytochrome C, and p21 (Santa Cruz Biotech, Santa Cruz, CA) were used to study cell death pathways. GAPDH (Millipore Corporation, Temecula, CA) was used as a loading control for Western blotting. Secondary antibodies included horseradish peroxidase conjugated anti-rabbit and anti-mouse immunoglobulin antibodies (Santa Cruz Biotech). AnnexinV-fluorescein isothiocyanate (annexinV-FITC) detection kit (Biosource-Invitrogen, Camarillo, CA) was used to measure apoptosis.
Quantification of apoptosis.
Cell viability was examined morphologically after staining with trypan blue and by analysis of apoptosis using fluorescence activated cell sorting (FACS) after staining with annexinV-FITC and propidium iodide (PI). In brief, 1x10 6 
Measurement of ROS.
Intracellular ROS concentration was determined by using cell permeable dyes as described previously.(21, 22) In brief, cells were washed with PBS and re-suspended in 1ml of RPMI containing 5μM H 2 DCF-DA and incubated at 37°C for 30 minutes in the dark. ROS were measured by oxidation of H 2 DCFDA to DCF.
Fluorescence intensity was read by flow cytometry on the FL1 channel.
Western blot analysis.
Cells were centrifuged, washed with cold PBS, and lysed on ice for 30 minutes in lysis buffer containing protease and phosphatase inhibitors. Protein concentrations were determined with the Bio-Rad protein assay kit (Bio-Rad, Hercules,CA). Total protein (50μg) was electrophoresed on 12% SDS polyacrylamide gels and bands were visualized by chemiluminescence (Amersham Biosciences, Buckinghamshire, United Kingdom).
Measurement of mitochondrial membrane potential (MMP).
MMP was measured by flow cytometry using JC-1 staining. Cells were washed with Hank's buffered salt solution (HBBS) and incubated with 4 μg/ml JC-1 dye in HBSS for 15 minutes at 37 o C in an incubator. Cells were washed with HBSS and immediately subjected to flow cytometric analysis.
Cell cycle analysis.
Distinct phases of the cell cycle were distinguished by PI flow cytometry. Cells were washed in ice cold PBS, fixed in 70% ethanol, and stained for 30 minutes at 37°C with PI (50μg/ml PI in hypotonic sodium citrate solution containing 50μg/ml RNase) followed by flow cytometric analysis. The percentage of cells in G1, S, and G2/M phases were determined using the cell cycle analysis program Modfit LT (Verity Software, Topsham, ME).
Protein extracts and electrophoretic mobility shift assay (EMSA).
EMSA was performed using a gel-shift kit from Panomics (Fremont, CA). In brief, cellular extracts were prepared as described earlier and protein concentrations were determined using Bio-Rad's protein assay reagent.
The cellular extracts were then incubated with a biotin labeled NF-ĸB probe for 30 minutes at 15 o C. The extracts were electrophoresed on a 6% polyacrylamide gel and transferred to a Hybond nylon membrane (Pall Corporation, Ann Arbor, MI). The membrane was blocked for 15 minutes in blocking buffer followed by 15 min incubation with streptavidin-HRP antibody in the blocking buffer. Membranes were washed three times, developed using the detection kit and visualized using hyperfilm ECL (Amersham Biosciences, Buckinghamshire, United Kingdom).
Real time polymerase chain reaction (RT-PCR) analysis.
Taqman Gene Expression Assays for selected genes were obtained from Applied Biosystems Inc. (Foster City, CA). One-step RT-PCR was carried out in triplicate on 25ng of total RNA from each sample on an ABI PRISM 7300 instrument according to the manufacturer's standard protocols. The mRNA levels for each gene were normalized to the amount of RNA in the well as measured in parallel using Ribogreen (Molecular Probes, Eugene, OR). The treated samples were then normalized to the vehicle control at that time point.
Microarray analysis.
The RNA expression profile was analyzed on custom Codelink oligonucleotide arrays (GE Biosciences, Piscataway, NJ), each containing 1857 gene probes, representing cellular cancer-related pathways, selected from the Codelink Human Genome arrays used in previous work. (11, 23) cRNA probes were prepared from the total RNA isolated from treated and control cells, and hybridized to the arrays using standard protocols (Codelink Protocol v2.1). Arrays were hybridized for 18 hours at 37°C, washed and detected with Strepatavidin-Alexa 647. They were scanned with a GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA) and the images were processed with Codelink 4.0 Batch Processing software. The data were then analyzed in Genespring (Agilent Inc., Santa Clara, CA); only genes passing quality filters ("G") and p-value cutoff of 0.05 were used in the analyses.
Statistics.
For all apoptosis experiments (annexinV/PI and MMP), values represent the mean from three independent studies done in triplicate. Differences in groups were assessed by student t test and were considered statistically significant at p<0.05, <0.01, and <0.001. For the experiments combining bortezomib and PCI-24781, synergy was determined using isobologram analysis based on the method of Chou and Talay using the Calcusyn 
Results
PCI-24781 induced apoptosis in Hodgkin lymphoma and non-Hodgkin's lymphoma cell lines.
The lymphoma cell lines were exposed to 0.5µM to 2µM PCI-24781 for 48 hours. PCI-24781 induced apoptosis in all cell lines in a dose-dependent manner ( Figure 1A ). The IC 50 of PCI-24781 was 0.5µM for Ramos, 0. An increase in ROS was also observed with combination PCI-24781/bortezomib and in Ramos as shown in Figure 3C . Cells were co-incubated with catalase, a free radical scavenger that degrades hydrogen peroxide. In Ramos ( Figure 3D ) and L428 ( Figure 3E The involvement of caspases in PCI-24781 and bortezomib-induced apoptosis was assessed by detection of cleaved caspases and PARP by western blotting. As shown in Figure 4C , both agents induced caspase 8 and 9
cleavage when used alone. However, the combination of bortezomib and PCI-24781 resulted in markedly increased cleaved caspase 8 and caspase 9 compared with either agent alone ( Figure 4C ). Cleavage of caspase 3
and PARP was observed following treatment of cells with bortezomib or PCI-24781. To assess the importance of caspase activation in bortezomib and/or PCI-24781-induced cell death, cells were co-incubated with the broad spectrum caspase inhibitor, Q-VD-OPh. Figure 4D shows that PCI-24781/bortezomib-indcued cell death in L428 and Ramos cells was in part caspase-dependent.
Apoptosis is associated with cell cycle arrest and p21 upregulation.
Dose-dependent G2/M arrest occurred following treatment of Ramos and L428 cells with bortezomib ( Figure   5A ) that was accompanied by a decreased number of cells within the S and G1 phases. The treatment of cells with PCI-24781 resulted in G0/G1 arrest with a decrease in G2/M and S phase cell population ( Figure 5B ). The combination of bortezomib and PCI-24781 mimicked the effects of PCI-24781 alone. The biologic effects of HDACis are thought to be transduced at least in part by modifications of the acetylation state of histones.
Therefore, the effect of PCI-24781 and bortezomib on acetylation of histones was examined. Hyperacetylation of histone H3 and H4 was observed following PCI-24781 treatment, as expected ( Figure 5C ). Interestingly, bortezomib also provoked a small increase in the acetylation of histone H4, although to a much lesser extent .
However, the combination of PCI-24781 and bortezomib resulted in a significant increase in histone acetylation ( Figure 5C ). The promoter of the transcription of the CDK inhibitor for p21 (CDKN1A) is regulated by histone acetylation status, (27) and up-regulation of p21 has been reported with HDAC inhibitors. (28, 29) We observed increased protein levels of p21 with PCI-24781, and more so with the combination ( Figure 5D ).
Microarray analysis following PCI-24781 and/or bortezomib.
Gene expression profiling using the pathway analysis chip revealed a subset of genes whose expression was Table 1 .
The classical targets of both drugs were affected, including proteasome components and several HDACs (HDACs 1, 2, 7, 8) with bortezomib and PCI-24781 treatment, respectively. In addition to these, significant downregulation of genes in several pathways including cell cycle, proteasome, oxidative stress, and apoptosis were observed in response to PCI-24781 alone; these effects were enhanced in combination with bortezomib. In particular, it was observed that several anti-oxidant genes were downregulated by PCI-24781 alone and in combination with bortezomib, including thioredoxin-2 and thioredoxin reductase-2, heme oxygenase 2, catalase, glutathione reductase, and several glutathione reductases ( Table 1) . Some of these pathways have been previously linked with induction of apoptosis by these compounds. A marker for ROS induction, heme oxygenase 1 (HMOX-1), was also increased, but unlike HMOX-2, this gene may serve to facilitate apoptosis. It 
Inhibition of NF-ĸB.
To confirm the microarray analysis results, we measured the changes in mRNA and protein levels of several
NF-ĸB targets by other methods. Accordingly, quantitative RT-PCR analysis of known NF-ĸB targets including
NFĸB1 (p105, the precursor of the NF-ĸB subunit p50), c-Myc, and the two IKK catalytic subunits IKKα (IKK1) and IKKβ (IKK2) were measured. PCI-24781 alone markedly decreased NF-ĸB1, and to a lesser extent c-Myc and IKKβ ( Figure 6A ). Moreover, a notable decrease in all four of these transcripts was seen with PCI-24781/bortezomib in combination. Finally, we analyzed the NF-ĸB subunit p65 (Rel A) and c-Myc protein levels in response to bortezomib and PCI-24781 alone and in combination, by Western blotting ( Figure 6B ).
NF-ĸB p65 protein levels did not change significantly, in agreement with the microarray results, whereas c-Myc protein was decreased by PCI-24781 alone and PCI-24781/bortezomib.
To further determine the effect that combined exposure of bortezomib and PCI-24781 has on NF-ĸB DNA binding activity, electrophoretic mobility shift analysis was performed ( Figure 6C) . A decrease in NF-ĸB activity was observed with 10nM-20nM bortezomib and 1µM-2µM PCI-24781 alone and in combination in
Ramos and L428 cells. These findings support the concept that NF-ĸB signaling is a key component in the cell death pathways induced by PCI-24781 alone and in combination.
Discussion
In this work, we show that the novel broad spectrum hydroxamic acid-based HDACi, PCI-24781, induced dose- In this work, we also present the first microarray analysis of a HDACi/bortezomib combination response; we found that PCI-24781 downregulates the expression of many anti-oxidant genes including TXN2 and TNXRD2.
The results of the pathway analysis presented here suggest that, in these lymphoma cell lines, the single-agent The results presented here also delineate other molecular mechanisms that may contribute to the synergy of PCI-24781 and bortezomib. Of note, it has been reported that the oxidative stress marker HMOX-1, which was upregulated in this study, can inhibit NF-ĸB activation by preventing its translocation into the nucleus and inhibiting the degradation of IĸB, (32, 33) and indeed that it may enhance bortezomib-induced cell death in leukemic cells. (34) The activation of NF-ĸB is known to play a critical role in the oncogenesis of lymphoid malignancies. (35, 36) In the present study, treatment with PCI-24781 alone led to significant downregulation of several components of the proteasome complex as well as many NF-ĸB target genes. The combination of PCI-24781 and bortezomib resulted in further down-regulation of several NF-ĸB target genes including c-Myc (at protein and mRNA levels), myc-regulated genes, as well as the two catalytic subunits of IKK (IKKα and IKKβ) (Table 1 and Figure 6A ). More directly, the DNA-binding activity was also decreased following treatment of cells with these compounds as shown by the gel shift assay. The canonical NF-ĸB pathway appeared to more dominant in the lymphoma cells studied here as the PCI-24781/bortezomib combination primarily affected the p65/p50 complex through reduction of IKK activity and p50 expression (and its precursor, NF-ĸB1), which led to decreased nuclear translocation and decreased binding of NF-ĸB to its target promoters. HDACi that increase acetylation of proteins require an intact NF-ĸB signaling pathway to induce cell cycle arrest in human myeloid leukemia cells.(37) Interestingly, it has also been noted that several anti-oxidant genes are also regulated by NF-ĸB, and that activation of the NF-ĸB pathway plays a vital role in the oxidative stress response of tumor cells (38) suggesting that ROS induction, downregulation of expression of thioredoxin-2 and other anti-oxidant genes and inhibition of NF-ĸB activation could all act synergistically in the activity of the PCI-24781/bortezomib combination in lymphoma.
The mode of apoptosis induction by the PCI-24781/bortezomib combination involved activation of both extrinsic (via caspase-8) and intrinsic (via caspase-9) caspase pathways. Compared to either agent alone, PCI-24781 and bortezomib together led to highly increased levels of cleaved caspase-8, caspase-9, caspase-3, and PARP. The upregulation of several members of the TNF receptor superfamily may lead to the activation of the extrinsic pathway, while the activation of the intrinsic pathway via caspase-9 is consistent with the relatively early loss of mitochondrial potential ∆Ψ m that is observed here. Moreover, cell death was caspase-dependent as shown with pan-caspase inhibition, which inhibited apoptosis induced by PCI-24781 alone and combined with bortezomib. It is also interesting that PCI-24781 decreased expression of c-FLIP and the pro-survival BIRC family members including survivin and apollon, which may all prevent cytochrome c release and caspase activation. Further studies are needed to confirm the detailed mechanism of caspase activation in response to PCI-24781 and bortezomib in lymphoma.
Finally, PCI-24781 mediated a prominent arrest of the lymphoma cells in the G0/G1 phase of the cell cycle, resulting in a marked decrease in S phase. This blockade of the cell cycle was accompanied by increased expression of p21, a cyclin-dependent kinase (CDK) inhibitor that plays an important role in cell cycle arrest during the G1 or G2 phase.(39) Prominent increases were also observed in other CDK inhibitors, including CDKN1B, CDKN1C, and CDKN2B (Table 1) . Concordant decreases in many cyclins and CDKs, most prominently CDK4 and cyclin A2, likely contributed to the dramatic increase in G1 arrest and subsequent apoptosis in these lymphoma cell lines. As expected with an HDACi, there was also an accumulation of acetylated histone H3 and H4 with PCI-24781 treatment in these cells, which was synergistically increased by adding bortezomib; however, we and others have shown that histone acetylation is not directly correlated with sensitivity. (11, 40) It is likely however, that the enhanced accumulation of p21 is due to increased histone acetylation in these cells. (27) Further, histone acetylation (and its surrogate for compounds that inhibit HDAC6, tubulin acetylation) has proved to be an important and sensitive pharmacodynamic marker of HDAC activity in clinical studies, including the PCI-24781 studies currently underway.
In summary, our results show that the pan-HDACi, PCI-24781, when used alone exhibited dose-dependent apoptosis in a Hodgkin lymphoma cell line and several non-Hodgkin's lymphoma cell lines. Furthermore, the combination of PCI-24781 with bortezomib was strongly synergistic in these cells. Apoptosis induced by PCI-24781 alone and by the combination was ROS-and caspase-dependent. Disruption of the cellular redox state with production of ROS and downregulation of oxidative stress response genes may represent an important mechanism underlying lymphoma cell death in response to PCI-24781 alone and combined with bortezomib.
We showed that the NF-ĸB pathway, which is a major regulator of the oxidative stress response in cells, was inhibited by PCI-24781 alone and further when combined with bortezomib. Finally, we showed that acetylation of histones and re-expression of p21 was greatly enhanced when bortezomib was added to PCI-24781. Thus, the combination of PCI-24781/bortezomib triggered cell death through interacting mechanisms including ROS generation, mitochondrial disruption, proteasome and NF-ĸB inhibition, cell cycle arrest, and caspase activation. Taken together our data suggest that PCI-24781 has potential therapeutic value in Hodgkin lymphoma and non-Hodgkin's lymphoma as a single-agent and in combination with bortezomib. 
